Ovid Therapeutics reports Phase 1 OV350 study results via press release

Ovid Therapeutics Inc. reported that it has released new information on its experimental therapy OV350.

Rhea-AI Filing Summary

Ovid Therapeutics Inc. reported that it has released new information on its experimental therapy OV350. The company issued a press release announcing results from its Phase 1 study of OV350, an early-stage clinical trial that primarily evaluates safety, dosing, and how the drug behaves in the body. The press release, dated December 18, 2025, is attached as an exhibit to this report for investors and the public to review.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Ovid Therapeutics (OVID) disclose in this 8-K filing?

Ovid Therapeutics disclosed that it issued a press release announcing results from its Phase 1 study of OV350, attaching the release as an exhibit.

What is OV350 in the Ovid Therapeutics (OVID) filing?

OV350 is described as an investigational therapy for which Ovid reported results from a Phase 1 clinical study.

What stage of clinical development is OV350 in for Ovid Therapeutics (OVID)?

OV350 is in Phase 1 clinical development, which typically focuses on safety, tolerability, and dosing in humans.

How did Ovid Therapeutics (OVID) communicate the OV350 Phase 1 results?

The company communicated the OV350 Phase 1 results through a press release, which is filed as Exhibit 99.1 and incorporated by reference.

Where can investors find details of the OV350 Phase 1 results from Ovid Therapeutics (OVID)?

Detailed information is contained in the press release dated December 18, 2025, attached as Exhibit 99.1 to the report.

Who signed the Ovid Therapeutics (OVID) report related to OV350?

The report was signed on behalf of Ovid Therapeutics Inc. by Jeffrey Rona, Chief Business and Financial Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/18/2025 - 08:39 AM EST Learn about SEC filing dates

false 0001636651 0001636651 2025-12-18 2025-12-18

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 18, 2025

OVID THERAPEUTICS INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware		001-38085		46-5270895
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)
441 Ninth Avenue, 14th Floor New York, New York				10001
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 646-661-7661

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock par value $0.001 per share		OVID		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On December 18, 2025, Ovid Therapeutics Inc. issued a press release announcing results from its Phase 1 study of OV350. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release, dated December 18, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized

Date: December 18, 2025

OVID THERAPEUTICS INC.
By:		/s/ Jeffrey Rona
		Jeffrey Rona
		Chief Business and Financial Officer